Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Drugs and Diagnostics for Hematological Disorders: Global Markets

Enquire | Email | Print

Single User - $6,650       2 to 5 Users - $8,500       6 to 10 Users - $10,500       11to 20 Users - $12,500       21+ Users - $15,000
Published Date: Mar, 2013
Format: PDF
No of Pages: 429
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

REPORT HIGHLIGHTS

This report provides:

-An overview of the global market for drugs and diagnostics for hematological disorders.
-Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
-A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
-A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
-Delineation of drugs approved by the FDA for hematological disorders.
-Comprehensive profiles of key companies in the industry.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This report “PHM116A Hematological Disorders: Drug Technologies, Diagnostics and Global Markets” provides an overview of the current and potential global market for hematological disorders, treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of hematological disorders and blood cancers, therapy and technology, and utilization of the various therapeutic and diagnostic modalities to prevent and treat these disorders. The report’s focus is on hematological disorder treatment strategies such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview on hematological disorders and staging, diagnostic tests and technologies. Important trends in the field of hematological disorders and cancer research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2017 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the hematological disorders and blood cancer market.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. Some of these ailments affect children and the elderly. This study looks at most types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers.

This BCC market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy and also nutrition therapy.

INTENDED AUDIENCE

This report is an exhaustive study on the global hematological disorders and blood cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in hematological disorders and blood cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2010 to 2017 and also covers commercial prospects for hematological disorders and cancer diagnostic assays, current tests in use and their future.

SCOPE OF THE STUDY

The scope of this study is testing, screening technology and also therapeutics markets for hematological disorders and blood cancers. The report also includes the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends and new developments.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2017. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of prostate cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.

A comprehensive and exhaustive search of the literature on hematological disorders and blood cancers, assay development and already-marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

Chapter- 1: INTRODUCTION - Complimentary 3 $0
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC REPORTS
BCC ON-LINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 3 $150
Table Summary : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017
Figure Summary : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017

Chapter- 3: OVERVIEW 57 $1086
BLOOD DISEASES
BLOOD DISORDERS
HEMOGLOBIN DISORDERS
HEMOSTASIS
BLEEDING DISORDERS
HEMOPHILIA
WHITE BLOOD CELL DISORDERS
BLOOD DISORDERS AFFECTING PLATELETS
EOSINOPHILS AND DISORDERS
BASOPHILS AND DISORDERS
PLASMA CELL DISORDERS
Table 1 : KEY BLOOD DISORDERS
Table 2 : MALIGNANT BLOOD DISORDERS
Table 3 : NON-MALIGNANT BLOOD DISORDERS

Chapter- 4: HEMATOLOGICAL CANCERS 11 $210
CLASSIC CLASSIFICATION
ACUTE MYELOID LEUKEMIA
CHRONIC MYELOID LEUKEMIA
ACUTE LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA
HODGKIN LYMPHOMA
NON-HODGKIN LYMPHOMA
MULTIPLE MYELOMA
MYELODYSPLASTIC SYNDROME
Table 35 : HEMATOLOGICAL CANCERS (BLOOD CANCERS)

Chapter- 5: HEMATOLOGICAL CANCERS: LEUKEMIA 29 $553
LYMPHOCYTIC LEUKEMIAS
MYELOGENOUS LEUKEMIAS
DRUG THERAPIES FOR BLOOD CANCERS
CONCLUSIONS

Chapter- 6: HEMATOLOGICAL CANCERS: LYMPHOMA 15 $286
OVERVIEW
LYMPHOMA CAUSES
CLASSIFICATION

Chapter- 7: HEMATOLOGICAL CANCERS: MYELOMA 14 $267
OVERVIEW
COMPLICATIONS OF MYELOMA
TYPES OF MYELOMA
INCIDENCE
DIAGNOSIS
STAGING
CONCLUSIONS

Chapter- 8: HEMATOLOGICAL CANCER: MYELODYSPLASTIC SYNDROMES 12 $229
CLASSES
INTERNATIONAL PROGNOSTIC SCORING SYSTEM
DIAGNOSIS AND TESTS
PROGNOSIS AND TREATMENT OPTIONS
CHEMOTHERAPY
SUPPORTIVE CARE
DRUG PROFILES
CONCLUSIONS
Table 84 : CHARACTERISTICS OF MDS
Table 85 : MDS CAUSES
Table 86 : MDS OR AML: THREE CATEGORIES

Chapter- 9: HEMATOLOGICAL CANCERS: MYELOPROLIFERATIVE DISORDERS 31 $591
TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
CLASSIFICATION: WHO
STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS
POLYCYTHEMIA VERA
CHRONIC IDIOPATHIC MYELOFIBROSIS
ESSENTIAL THROMBOCYTHEMIA
CHRONIC NEUTROPHILIC LEUKEMIA
CHRONIC EOSINOPHILIC LEUKEMIA
SUMMARY

Chapter- 10: WORLDWIDE INCIDENCE: BLOOD DISORDERS AND BLOOD CANCER 70 $1334
INDIA
KENYA
WORLDWIDE INCIDENCE OF BLOOD CANCER
BLOOD DISEASES AND INCIDENCE
BLEEDING DISORDERS
CLOTTING DISORDERS
Table 115 : CANCER KEY FACTS
Table 116 : INCREASE IN CANCER BURDEN: FACTORS

Chapter- 11: HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL MARKET PERSPECTIVE 28 $534
HEMATOLOGICAL MALIGNANCIES

Chapter- 12: BLOOD DISEASES TREATMENTS MARKET 53 $1010
THERAPEUTIC DRUGS AND MARKET

Chapter- 13: HEMATOLOGICAL CANCER THERAPIES: MARKET 62 $1181
OVERVIEW

Chapter- 14: PATENT LANDSCAPE AND CURRENT DEVELOPMENTS 16 $305
HEMATOLOGICAL CANCER DRUGS: PATENT EXPIRY
NEW APPROVALS
NEW HEMATOLOGICAL CANCER DRUGS
NEWS AND DEVELOPMENT
DRUGS IN DEVELOPMENT
OTHER DEVELOPMENTS
BLOOD DISORDERS NEWS
ACQUISATIONS
Table 281 : MAJOR DRUGS: PATENT EXPIRY
Table 282 : KEY DRUGS: PATENT EXPIRY
Table 283 : DRUGS LOSING PATENT PROTECTION BY 2015 AND THEIR GLOBAL SALES IN 2010

Chapter- 15: SELECTED COMPANY PROFILES 18 $343
ABBOTT LABORATORIES
ABON PHARMACEUTICALS
AMBIT BIOSCIENCES
AMGEN
AMPHASTAR PHARMACEUTICALS
ARIAD PHARMACEUTICALS
ASTELLAS PHARMA US
ASTRAZENECA
BAXTER HEALTHCARE CORPORATION
BAYER HEALTHCARE PHARMACEUTICALS
BIOGEN IDEC
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
C.R. BARD
CELGENE CORPORATION
CZ BIOMED CORP.
DECIPHERA PHARMACEUTICALS
DIAGNOCURE
EISAI INC.
ELI LILLY AND COMPANY
ENZON PHARMACEUTICALS
EXELIXIS
GE HEALTHCARE
GENMAB INC.
GILEAD SCIENCES
GLAXOSMITHKLINE
HOLOGIC
HORIBA LTD.
JOHNSON & JOHNSON
MEDKOO BIOSCIENCES
MOMENTA PHARMACEUTICALS
NOXXON PHARMA AG
OPKO HEALTH
PFIZER
PHARMACYCLICS
PORTOLA PHARMACEUTICALS INC.
ROCHE DIAGNOSTICS
SANOFI
SIEMENS AG
SPECTRUM PHARMACEUTICALS
TEVA PHARMACEUTICAL INDUSTRIES LTD.
THE MEDICINES COMPANY
WATSON PHARMACEUTICALS INC.
YM BIOSCIENCES INC.

Chapter- 16: REFERENCES 7 $133

List of Tables

Summary Table : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, THROUGH 2017
Table 1 : KEY BLOOD DISORDERS
Table 2 : MALIGNANT BLOOD DISORDERS
Table 3 : NON-MALIGNANT BLOOD DISORDERS
Table 4 : TYPE OF BLOOD CELLS AND FUNCTIONS
Table 5 : BLOOD CELLS AND FUNCTION
Table 6 : THREE MAJOR TYPES OF ANEMIA
Table 7 : ANEMIA: MAJOR CATEGORIES
Table 8 : SYMPTOMS OF ANEMIA
Table 9 : TYPES OF ANEMIA
Table 10 : DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY
Table 11 : DRUGS: CAUSE OF FOLATE DEFICIENCY
Table 12 : KEY FACTS
Table 13 : LAB TESTS FOR ANEMIA
Table 14 : HEMOSTASIS: THREE MAJOR STEPS
Table 15 : DRUGS THAT EFFECT ACTIVITY OF PLATELETS
Table 16 : ANTICOAGULANTS THAT ACT ON THROMBIN
Table 17 : BLEEDING DISORDERS
Table 18 : BLEEDING DISORDERS: SYMPTOMS
Table 19 : SIGNS AND TESTS
Table 20 : KEY CHARACTERISTICS: HEMOPHILIA
Table 21 : FVIII INHIBITORS
Table 22 : MEDICATIONS FOR TREATING HEMOPHILIA
Table 23 : FACTOR VIII PRODUCTS
Table 24 : ANTIFIBRINOLYTICS
Table 25 : ANTIHEMOPHILIC AGENTS
Table 26 : FORMATION OF THROMBUS
Table 27 : CAUSES FOR NEUTROPENIA
Table 28 : WHITE BLOOD CELLS AND DISEASES
Table 29 : CAUSE OF SECONDARY THROMBOCYTOSIS
Table 30 : DIAGNOSTIC TESTS
Table 31 : MEDICINES FOR THROMBOCYTHEMIA
Table 32 : CAUSES OF THROMBOCYTOPENIA
Table 33 : SIGNS OF EXTERNAL BLEEDING
Table 34 : COMMON DRUGS TO TREAT EOSINOPHILIA
Table 35 : HEMATOLOGICAL CANCERS (BLOOD CANCERS)
Table 36 : RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN THE U.S.
Table 37 : TYPES OF HEMATOLOGICAL CANCERS
Table 38 : FDA APPROVED DRUGS FOR HEMATOLOGY, 2012
Table 39 : NEW HEMATOLOGY DRUG APPROVALS, 2012
Table 40 : FDA APPROVED DRUGS FOR HEMATOLOGY, 2011
Table 41 : APPROVED FDA DRUGS FOR HEMATOLOGICAL DISEASES, 1996-2010
Table 42 : TYPES OF LEUKEMIA
Table 43 : TYPES OF LEUKEMIA AND KEY FEATURES
Table 44 : DIAGNOSTIC EXAMS FOR LEUKEMIA
Table 45 : ADDITIONAL TESTS
Table 46 : PCR TESTS
Table 47 : NON-LABORATORY TESTS
Table 48 : COMMON TREATMENTS USED TO FIGHT LEUKEMIA
Table 49 : NEWER CLASSES OF DRUGS
Table 50 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATMENT
Table 51 : DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Table 52 : DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Table 53 : DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA (AML)
Table 54 : DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
Table 55 : T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN
Table 56 : FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS
Table 57 : CHEMOTHERAPY DRUGS FOR CML
Table 58 : CHEMOTHERAPY DRUGS FOR CLL
Table 59 : TARGETED THERAPY DRUGS
Table 60 : ADVANTAGES OF RADIOIMMUNOTHERAPY
Table 61 : COMMON RADIATION TREATMENTS: LEUKEMIA
Table 62 : PAIN MEDICATIONS
Table 63 : EMERGING THERAPIES FOR LEUKEMIA
Table 64 : CAUSES FOR LYMPHOMA
Table 65 : LYMPHOMA TYPES
Table 66 : STAGING FOR HL AND NHL TUMORS
Table 67 : MATURE B-CELL NEOPLASMS
Table 68 : MATURE T-CELL AND NATURAL KILLER (NK) CELL NEOPLASMS
Table 69 : HODGKIN LYMPHOMA
Table 70 : IMMUNODEFICIENCY-ASSOCIATED LYMPHO- PROLIFERATIVE DISORDERS
Table 71 : SYMPTOMS OF LYMPHOMA
Table 72 : FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS
Table 73 : IMAGING TESTS
Table 74 : HL, THE INTERNATIONAL PROGNOSTIC INDEX
Table 75 : THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL
Table 76 : PROMISING THERAPIES FOR TREATING LYMPHOMA
Table 77 : PROGNOSTIC INDICATORS FOR MYELOMA
Table 78 : OTHER BONE MARROW TESTS
Table 79 : MYELOMA: STAGING CRITERIA
Table 80 : MYELOMA'S RESPONSE TO TREATMENT
Table 81 : SUPPORTIVE CARE
Table 82 : DRUGS FOR MULTIPLE MYELOMA
Table 83 : EMERGING THERAPIES FOR MYELOMA
Table 84 : CHARACTERISTICS OF MDS
Table 85 : MDS CAUSES
Table 86 : MDS OR AML: THREE CATEGORIES
Table 87 : MYELODYSPLASTIC SYNDROMES: KEY FACTS
Table 88 : FAB CLASSIFICATION OF MDS
Table 89 : THE 2008 WHO CLASSIFICATION OF MDS
Table 90 : INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS AND PROGNOSIS
Table 91 : CHANGES IN CELLS AND MDS
Table 92 : CHRONIC MYELOPROLIFERATIVE DISORDERS
Table 93 : CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE 2008 WHO CLASSIFICATION SCHEME
Table 94 : MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS
Table 95 : DIAGNOSTIC TESTS
Table 96 : SYMPTOMS OF POLYCYTHEMIA VERA
Table 97 : BLOOD TESTS FOR POLYCYTHEMIA VERA
Table 98 : TREATMENT FOR POLYCYTHEMIA VERA
Table 99 : CAUSATIVE FACTORS FOR MYELOFIBROSIS
Table 100 : COMPLICATIONS FROM MYELOFIBROSIS
Table 101 : WHO DIAGNOSTIC CRITERIA FOR PMF
Table 102 : RISK FACTORS
Table 103 : IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS
Table 104 : PROGNOSIS
Table 105 : TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS
Table 106 : SOMATIC MUTATIONS
Table 107 : CAUSES OF THROMBOCYTOSIS
Table 108 : SYMPTOMS
Table 109 : ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA
Table 110 : TREATMENT OF ET
Table 111 : TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA
Table 112 : CHRONIC EOSINOPHILIC LEUKEMIA: SYMPTOMS
Table 113 : TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA
Table 114 : CURRENT DRUGS
Table 115 : CANCER KEY FACTS
Table 116 : INCREASE IN CANCER BURDEN: FACTORS
Table 117 : CANCER CASES AND TREATMENT COST IN INDIA, 2008-2010
Table 118 : WORLDWIDE INCIDENCE OF BLOOD CANCER, 2008
Table 119 : WORLDWIDE INCIDENCE OF BLOOD CANCER IN MEN, 2008
Table 120 : WORLDWIDE INCIDENCE OF BLOOD CANCER IN WOMEN, 2008
Table 121 : TOP 10 COUNTRIES' CANCER RATES
Table 122 : ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE U.S., 2010 AND 2011
Table 123 : ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2011
Table 124 : ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE U.S., 2012
Table 125 : GLOBAL INCIDENCE OF LEUKEMIA, 2010
Table 126 : LEUKEMIA INCIDENCE IN THE U.S.
Table 127 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
Table 128 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., ADULTS AND CHILDREN, 2011
Table 129 : APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE U.S., 2008
Table 130 : LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011
Table 131 : TYPES OF LEUKEMIA IN ADULTS IN THE U.S.
Table 132 : ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012
Table 133 : INCIDENCE RATES BY RACE, 2005-2009
Table 134 : THE FIVE-YEAR RELATIVE SURVIVAL RATES, 2001-2007
Table 135 : ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011
Table 136 : LEUKEMIA STATISTICS IN THE U.K.: NUMBER OF NEW CASES, INCIDENCE RATES BY GENDER PER 100,000 POPULATION, 2008
Table 137 : ACS ESTIMATES FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL) INCIDENCE IN THE U.S., 2012
Table 138 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
Table 139 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
Table 140 : HODGKIN LYMPHOMA WORLDWIDE, 2008
Table 141 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
Table 142 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
Table 143 : HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008
Table 144 : ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE U.S., 2012
Table 145 : ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE U.S., 2011 AND 2012
Table 146 : ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011 AND 2012
Table 147 : NEW CASES OF LYMPHOMA BY GENDER, 2011
Table 148 : ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011
Table 149 : AGE-SPECIFIC INCIDENCE RATES, BY GENDER, FOR NHL
Table 150 : INCIDENCE RATES BY RACE, 2005-2009
Table 151 : DEATH RATES BY RACE, 2005-2009
Table 152 : STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008
Table 153 : NON-HODGKIN LYMPHOMA IN THE U.K.: NUMBER OF NEW CASES, INCIDENCE, 2009
Table 154 : NON-HODGKIN LYMPHOMA DEATH IN THE U.K. MORTALITY, 2010
Table 155 : ESTIMATED HODGKIN LYMPHOMA STATISTICS IN THE U.K., 2008
Table 156 : HODGKIN'S LYMPHOMA IN THE U.K., 2008
Table 157 : MYELOMA INCIDENCE WORLDWIDE, 2008
Table 158 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
Table 159 : MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
Table 160 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
Table 161 : ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE U.S., 2011 AND 2012
Table 162 : ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER, 2011 AND 2012
Table 163 : INCIDENCE RATES BY RACE AND GENDER, 2005-2009
Table 164 : DEATH RATES BY RACE AND GENDER, 2005-2009
Table 165 : DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, 2002-2008
Table 166 : MYELOMA STATISTICS IN THE U.K. NUMBER OF NEW CASES: INCIDENCE RATES PER 100,000 POPULATION, 2009
Table 167 : MYELOMA NUMBER OF DEATHS IN THE U.K. MORTALITY RATES PER 100,000 POPULATION, 2010
Table 168 : ESTIMATED NEW CASES FOR MDS IN THE U.S., 2012
Table 169 : GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, THROUGH 2017
Table 170 : KEY PRODUCTS
Table 171 : GLOBAL MAJOR PLAYERS IN THE HEMATOLOGY MARKET
Table 172 : FLOW CYTOMETRY 171: KEY PLAYERS
Table 173 : FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST, THROUGH 2017
Table 174 : MAJOR FLOW CYTOMETRY APPLICATIONS
Table 175 : CELL ANALYZERS: KEY PLAYERS
Table 176 : HEMATOLOGY TESTS
Table 177 : COMPLETE BLOOD COUNT: COMPONENTS MEASURED
Table 178 : TESTS INCLUDED IN A CHEMISTRY SCREEN
Table 179 : CHEMISTRY SCREEN
Table 180 : URINE TESTS AND APPLICATIONS
Table 181 : IVD PRODUCTS MARKET: SALES AND FORECAST, THROUGH 2017
Table 182 : UNITED STATES: IVD MARKET SALES AND FORECAST, THROUGH 2017
Table 183 : GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND FORECAST, THROUGH 2017
Table 184 : GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES AND FORECAST, THROUGH 2017
Table 185 : KEY PLAYERS IN THE IMMUNOASSAYS MARKET
Table 186 : MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST, THROUGH 2017
Table 187 : MAJOR PLAYERS: MOLECULAR DIAGNOSTICS MARKET
Table 188 : THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND FORECAST, THROUGH 2017
Table 189 : GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST, THROUGH 2017
Table 190 : THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND FORECAST, THROUGH 2017
Table 191 : MARKET PLAYERS
Table 192 : GLOBAL BLOOD DISORDER MARKET, THROUGH 2017
Table 193 : GLOBAL BLOOD DISORDER MARKET SHARE, 2010 AND 2017
Table 194 : PATENT EXPIRIES OF MAJOR BLOCKBUSTERS
Table 195 : KEY PLAYERS: PRODUCTS AND MARKET SHARE, 2010
Table 196 : MARKET DRIVERS
Table 197 : MARKET RESTRAINTS
Table 198 : ANEMIA TREATMENT MARKET, THROUGH 2017
Table 199 : ERYTHROPOIETIN STIMULATING AGENTS (ESAS)
Table 200 : KEY ANEMIA DRUGS SALES, 2010-2012
Table 201 : NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012
Table 202 : GLOBAL NEORECORMON/EPOGIN SALES, 2009
Table 203 : COMMON ANEMIA TREATMENTS
Table 204 : AKEBIA THERAPEUTICS ANEMIA DRUG IN DEVELOPMENT-AKB-6548
Table 205 : GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND FORECAST, THROUGH 2017
Table 206 : LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET
Table 207 : GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST, THROUGH 2017
Table 208 : GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2017
Table 209 : ANTIPLATELET AND ANTICOAGULANT DRUGS
Table 210 : ANTIPLATELET DRUGS (PLATELET ADP ANTAGONISTS): SALES AND FORECAST, THROUGH 2017
Table 211 : U.S. SALES: PLAVIX, 2012
Table 212 : GLOBAL SEMULOPARIN SALES AND FORECAST, THROUGH 2017
Table 213 : ANTITHROMBOTIC AGENTS (BY PHARMACOLOGICAL CLASS): SALES AND FORECAST, 2010-2017
Table 214 : XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC (VAT) INDICATIONS
Table 215 : ANTITHROMBOTIC AGENTS IN DEVELOPMENT
Table 216 : ACTIVASE: SALES AND FORECAST, THROUGH 2017
Table 217 : ANGIOMAX: SALES AND FORECAST, 2010-2017
Table 218 : KEY PLATELET AGGREGATION INHIBITOR DRUG SALES AND FORECAST, 2010-2017
Table 219 : PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS
Table 220 : PLATELET INHIBITOR: PIPELINE DRUGS
Table 221 : THROMBOSIS MARKET: PIPELINE DRUGS
Table 222 : GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST, THROUGH 2017
Table 223 : KEY DRUGS
Table 224 : GROWTH FACTORS FOR TREATING NEUTROPENIA
Table 225 : WORLDWIDE SALES OF NEULASTA/NEUPOGEN, 2010-2012
Table 226 : SARGRAMOSTIM SALES, 2010
Table 227 : COMPANIES IN EUROPE WITH SHORT-ACTING FILGRASTIMS IN PHASE 3 CLINICAL DEVELOPMENT
Table 228 : HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST, THROUGH 2017
Table 229 : KEY PLAYERS IN THE HEMOPHILIA A THERAPEUTICS MARKET
Table 230 : KEY HEMOPHILIA DRUGS
Table 231 : GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, 2010
Table 232 : GLOBAL BLOOD DISORDERS PIPELINE MOLECULES
Table 233 : CYTOTOXIC THERAPIES MARKET INDICATIONS
Table 234 : LIST OF LEUKEMIA MEDICATIONS
Table 235 : GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
Table 236 : U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 237 : EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 238 : JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 239 : MAJOR PLAYERS IN THE LEUKEMIA MARKET
Table 240 : LEUKEMIA: CATEGORIES
Table 241 : GLOBAL LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
Table 242 : U.S. LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
Table 243 : EUROPEAN LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
Table 244 : JAPAN'S LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
Table 245 : GLOBAL LEUKEMIA MARKET BY GEOGRAPHICAL REGIONS: SALES AND FORECAST, THROUGH 2017
Table 246 : LEUKEMIA MARKET SHARE FORECAST, 2011-2017
Table 247 : CHRONIC MYELOGENOUS LEUKEMIA (CML) MARKET: SALES AND FORECAST, THROUGH 2017
Table 248 : DRUG CLASSES FOR LEUKEMIA DRUG DEVELOPMENT
Table 249 : KEY CHRONIC MYELOGENOUS LEUKEMIA (CML) SALES AND FORECAST, 2010-2012
Table 250 : KEY CML MEDICINES AND COST
Table 251 : GLEEVAC: FDA APPROVALS
Table 252 : PIPELINE DRUGS FOR LEUKEMIA
Table 253 : ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, THROUGH 2017
Table 254 : MAJOR PLAYERS IN THE ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET
Table 255 : DRUGS FOR ALL TREATMENT
Table 256 : APPROVED DRUGS FOR ALL
Table 257 : GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SALES AND FORECAST, THROUGH 2017
Table 258 : KEY COMPANIES IN THE AML MARKET
Table 259 : CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET: SALES AND FORECAST, THROUGH 2017
Table 260 : ARZERRA: SALES AND FORECAST, 2010-2017
Table 261 : TREANDA SALES, THROUGH 2017
Table 262 : KEY PLAYERS IN THE CLL MARKET
Table 263 : TREATMENT GENERIC DRUGS USED IN COMBINATION FOR HODGKIN LYMPHOMA
Table 264 : TREATMENT DRUGS USED IN COMBINATION FOR NON-HODGKIN LYMPHOMA
Table 265 : NON-HODGKIN'S LYMPHOMA DRUG MARKET: SALES AND FORECAST, THROUGH 2017
Table 266 : RITUXIMAB SALES AND FORECAST, 2010-2012
Table 267 : RITUXAN: BIOSIMILARS IN DEVELOPMENT
Table 268 : REVLIMID SALES AND FORECAST, 2011 AND 2012
Table 269 : HODGKIN'S LYMPHOMA TREATMENT MARKET: SALES AND FORECAST, THROUGH 2017
Table 270 : MULTIPLE MYELOMA TREATMENT MARKET: SALES AND FORECAST, THROUGH 2017
Table 271 : DRUGS FOR THE MYELOMA MARKET
Table 272 : DRUGS IN DEVELOPMENT
Table 273 : TREANDA CLINICAL TRIALS IN RELAPSED AND/OR REFRACTORY MYELOMA
Table 274 : MARKET FOR MYELODYSPLASTIC SYNDROME, THROUGH 2017
Table 275 : APPROVED DRUGS FOR THE TREATMENT OF MDS
Table 276 : MARKET FOR MYELOPROLIFERATIVE DISORDERS, THROUGH 2017
Table 277 : JAK2 INHIBITORS IN DEVELOPMENT
Table 278 : RUXOLITINIB FORECAST, 2012 AND 2017
Table 279 : MARKET FOR MYELOFIBROSIS, THROUGH 2017
Table 280 : MARKET FOR POLYCYTHEMIA VERA, THROUGH 2017
Table 281 : MAJOR DRUGS: PATENT EXPIRY
Table 282 : KEY DRUGS: PATENT EXPIRY
Table 283 : DRUGS LOSING PATENT PROTECTION BY 2015 AND THEIR GLOBAL SALES IN 2010
Table 284 : BIOLOGICS: PATENT EXPIRY
Table 285 : NEW DRUG APRROVALS FOR BLOOD DISORDERS, 2012
Table 286 : NEW DRUG APRROVALS FOR HEMATOLOGICAL CANCERS, 2012

List of Figures

Summary Figure : HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL MARKETS, 2010-2017
Figure 1 : ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE U.S., 2010 AND 2011
Figure 2 : ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND MYELOMA IN THE U.S., 2011
Figure 3 : ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE U.S., 2012
Figure 4 : ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
Figure 5 : APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA IN THE UNITED STATES, 2008
Figure 6 : LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011
Figure 7 : ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012
Figure 8 : ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011
Figure 9 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
Figure 10 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE, 2008
Figure 11 : HODGKIN LYMPHOMA WORLDWIDE, 2008
Figure 12 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
Figure 13 : ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27 COUNTRIES, 2008
Figure 14 : HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008
Figure 15 : ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE U.S., 2012
Figure 16 : ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE U.S., 2011 AND 2012
Figure 17 : ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011 AND 2012
Figure 18 : NEW CASES OF LYMPHOMA BY GENDER, 2011
Figure 19 : ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011
Figure 20 : HODGKIN'S LYMPHOMA IN THE U.K., 2008
Figure 21 : MYELOMA INCIDENCE WORLDWIDE, 2008
Figure 22 : MYELOMA MORTALITY RATES WORLD WIDE, 2008
Figure 23 : MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
Figure 24 : MYELOMA MORTALITY RATES, WORLDWIDE, 2008
Figure 25 : ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE U.S., 2011 AND 2012
Figure 26 : ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER, 2011 AND 2012
Figure 27 : GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET, 2010-2017
Figure 28 : FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST, 2010-2017
Figure 29 : IVD PRODUCTS MARKET: SALES AND FORECAST, 2010-2017
Figure 30 : UNITED STATES: IVD MARKET SALES AND FORECAST, 2010-2017
Figure 31 : GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND FORECAST, 2010-2017
Figure 32 : GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES AND FORECAST, 2010-2017
Figure 33 : MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST, 2010-2017
Figure 34 : THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND FORECAST, 2010-2017
Figure 35 : GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST, 2012 AND 2017
Figure 36 : THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND FORECAST, 2012 AND 2017
Figure 37 : GLOBAL BLOOD DISORDER MARKET, 2010-2017
Figure 38 : ANEMIA TREATMENT MARKET, 2010-2017
Figure 39 : KEY ANEMIA DRUGS SALES, 2010-2012
Figure 40 : NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012
Figure 41 : GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND FORECAST, 2010-2017
Figure 42 : GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST, 2010-2017
Figure 43 : GLOBAL ANTIPLATELET DRUG MARKET, 2010-2017
Figure 44 : GLOBAL SEMULOPARIN SALES AND FORECAST, 2011-2017
Figure 45 : GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST, 2010-2017
Figure 46 : HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST, 2010-2017
Figure 47 : GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS FOR HEMOPHILIA, 2010
Figure 48 : GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
Figure 49 : U.S. CYTOTHERAPEUTICS MARKET, 2010-2017
Figure 50 : EUROPEAN CYTOTHERAPEUTICS MARKET, 2010-2017
Figure 51 : JAPANESE CYTOTHERAPEUTICS MARKET, 2010-2017
Figure 52 : GLOBAL LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
Figure 53 : U.S. LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
Figure 54 : EUROPEAN LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
Figure 55 : JAPAN'S LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
Figure 56 : GLOBAL LEUKEMIA MARKET BY GEOGRAPHICAL REGIONS: SALES AND FORECAST, 2010-2017
Figure 57 : CHRONIC MYELOGENOUS LEUKEMIA (CML) MARKET: SALES AND FORECAST, 2010-2017
Figure 58 : KEY CHRONIC MYELOGENOUS LEUKEMIA (CML) SALES AND FORECAST, 2010-2012
Figure 59 : ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, 2010-2017
Figure 60 : GLOBAL ACUTE MYELOID LEUKEMIA MARKET: SALES AND FORECAST, 2010-2017
Figure 61 : CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) MARKET: SALES AND FORECAST, 2010-2017
Figure 62 : NON-HODGKIN'S LYMPHOMA DRUG MARKET: SALES AND FORECAST, 2010-2017
Figure 63 : HODGKIN'S LYMPHOMA TREATMENT MARKET: SALES AND FORECAST, 2010-2017
Figure 64 : MULTIPLE MYELOMA TREATMENT MARKET: SALES AND FORECAST, 2010-2017
Figure 65 : MARKET FOR MYELODYSPLASTIC SYNDROME, 2010-2017
Figure 66 : MARKET FOR MYELOPROLIFERATIVE DISORDERS, 2010-2017
Figure 67 : MARKET FOR MYELOFIBROSIS, 2010-2017
Figure 68 : MARKET FOR POLYCYTHEMIA VERA, 2010-2017

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 378874, price: INR 403099, BCC Research

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online